Pfizer taps Triana to discover molecular glues for cancer and beyond in deal potentially worth $1.5B
Big Pharma is sticking to the recent molecular glue investment trend, with Pfizer now the latest major drugmaker to get in on the action.
All Posts in "Editor"
J&J, with adult approval in sight, posts adolescent myasthenia gravis data on $6.5B FcRn blocker
Johnson & Johnson has burnished the evidence for nipocalimab, adding a sliver of data in adolescents with generalized myasthenia gravis (gMG) to the growing case for its near-approval FcRn blocker.
Jasper dials up dose after complete responses come and go quickly in hives trial
Jasper Therapeutics has reported complete responses in 10 of the 12 chronic hives patients who received the high dose of its c-Kit antibody. But, with some patients relapsing within weeks, the biotech has begun trialing a higher dose in pursuit of deeper, more durable responses.
Novartis channels Gargamel, terminating midphase SMURF1 trial
Novartis has terminated a phase 2 trial of its SMURF1 inhibitor LTP001 in idiopathic pulmonary fibrosis (IPF) but will continue to advance the candidate in another indication.
Transgene’s viral cancer vaccine flunks midphase test—but subgroup signal spurs ongoing analysis
Transgene’s therapeutic vaccine candidate TG4001 has flunked a phase 2 solid tumor trial. But, while the prospect failed to improve progression-free survival (PFS), the French biotech is continuing to analyze aspects of the data including a “positive efficacy trend” in a prespecified subgroup before deciding on its next steps.
Lilly picks UK for first European Gateway Lab as part of $364M investment plan
Eli Lilly’s Gateway Labs is going global, with the U.K. government announcing today that the nation will host the first European branch of the incubator program.
Capricor cell therapy improves cardiac and upper limb function in phase 2 Duchenne muscular dystrophy victory lap
Capricor Therapeutics is taking a victory lap for their phase 2 Duchenne muscular dystrophy (DMD) trial. At three years, the San Diego-based company’s cell therapy deramiocel improved patients’ left ventricular ejection fraction and ability to use their upper limbs.
After axing its sole clinical prospect last year, Alaunos cuts ties with Precigen
Alaunos Therapeutics is axing an agreement with Precigen, giving up licensing rights to a personalized T-cell platform.
Bruker spools up spatial biology division from NanoString, Canopy assets
Bruker has formed a new, single division out of the various spatial biology assets it has acquired over the years.
Turnstone lays off 60% of staff, shakes up C-suite to keep cancer cell therapy on track
Turnstone Biologics is reducing its head count by 60% and shaking up its C-suite in order to keep the cash flowing to its sole clinical-stage candidate.
RFK Jr, noted vaccine sceptic, backs measles jab amid deadly US outbreak
Sad Case of The Youngest Person Ever Diagnosed With Alzheimer’s
Cell connects: Breaking barriers in stem cell communication through mRNA transfer
Fed-Batch Data Inadequate for Continuous Cultivation in Certain Systems
Pioneering work generates feline embryonic stem cells in boon for cats
Alzheimer’s Disease Could Be Influenced by HSV-1 Infections via Jumping Genes
RFK Jr. canceled flu vaccine meetings. What does that mean for fall shots?
What to know about the dangers of expired medications
Conservation focusing on birds of a feather may have mixed results
Cell connects: Breaking barriers in stem cell communication through mRNA transfer